Cerhan JR. Epidemiology of follicular lymphoma. Hematol Oncol Clin North Am. 2020;34:631–46. https://doi.org/10.1016/j.hoc.2020.02.001.

Google Scholar 

Casulo C, Byrtek M, Dawson KL, Zhou X, Farber CM, Flowers CR, et al. Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National LymphoCare Study. J Clin Oncol. 2015;33:2516–22. https://doi.org/10.1200/JCO.2014.59.7534.

Google Scholar 

Batlevi CL, Sha F, Alperovich A, Ni A, Smith K, Ying Z, et al. Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroups. Blood Cancer J. 2020;10:74. https://doi.org/10.1038/s41408-020-00340-z.

Google Scholar 

Casulo C, Larson MC, Lunde JJ, Habermann TM, Lossos IS, Wang Y, et al. Treatment patterns and outcomes of patients with relapsed or refractory follicular lymphoma receiving three or more lines of systemic therapy (LEO CReWE): a multicentre cohort study. Lancet Haematol. 2022;9:e289–300. https://doi.org/10.1016/S2352-3026(22)00033-3.

Google Scholar 

Neelapu SS, Chavez JC, Sehgal AR, Epperla N, Ulrickson M, Bachy E, et al. Three-year follow-up analysis of axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma (ZUMA-5). Blood. 2024;143:496–506. https://doi.org/10.1182/blood.2023021243.

Google Scholar 

Dreyling M, Fowler NH, Dickinson M, Martinez-Lopez J, Kolstad A, Butler J, et al. Durable response after tisagenlecleucel in adults with relapsed/refractory follicular lymphoma: ELARA trial update. Blood. 2024;143:1713–25. https://doi.org/10.1182/blood.2023021567.

Google Scholar 

Morschhauser F, Dahiya S, Palomba ML, Martin Garcia-Sancho A, Reguera Ortega JL, Kuruvilla J, et al. Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study. Nat Med. 2024;30:2199–207. https://doi.org/10.1038/s41591-024-02986-9.

Google Scholar 

Sehn LH, Bartlett NL, Matasar MJ, Schuster SJ, Assouline SE, Giri P, et al. Long-term 3-year follow-up of mosunetuzumab in relapsed or refractory follicular lymphoma after ≥2 prior therapies. Blood. 2025;145:708–19. https://doi.org/10.1182/blood.2024025454.

Google Scholar 

Linton KM, Vitolo U, Jurczak W, Lugtenburg PJ, Gyan E, Sureda A, et al. Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL-1): a phase 2 cohort of a single-arm, multicentre study. Lancet Haematol. 2024;11:e593–605. https://doi.org/10.1016/S2352-3026(24)00166-2.

Google Scholar 

Kim TM, Taszner M, Novelli S, Cho SG, Villasboas JC, Merli M, et al. Safety and efficacy of odronextamab in patients with relapsed or refractory follicular lymphoma. Ann Oncol. 2024;35:1039–47. https://doi.org/10.1016/j.annonc.2024.08.2239.

Google Scholar 

Ng LCK, Casulo C. Current landscape of frontline and relapsed follicular lymphoma trials. Blood Neoplasia. 2025;100131. https://doi.org/10.1016/j.bneo.2025.100131.

Page MJ, Moher D, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. BMJ. 2021;372:n160. https://doi.org/10.1136/bmj.n160.

Google Scholar 

Brooke BS, Schwartz TA, Pawlik TM. MOOSE Reporting Guidelines for Meta-analyses of Observational Studies. JAMA Surg. 2021;156:787–8. https://doi.org/10.1001/jamasurg.2021.0522.

Google Scholar 

Solal-Céligny P, Roy P, Colombat P, White J, Armitage JO, Arranz-Saez R, et al. Follicular lymphoma international prognostic index. Blood. 2004;104:1258–65. https://doi.org/10.1182/blood-2003-12-4434.

Google Scholar 

Wells G, Shea B, O’Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle–Ottawa Scale (NOS) for assessing the quality of non-randomized studies in meta-analysis. Available: https://www.ohri.ca/programs/clinical_epidemiology/oxford.asp. Accessed 2 November 2024.

Shapiro H, Shodimu V, Webb N. SA109 quality assessment tools for single-arm studies: a rapid review. Value Health. 2024;27:S635–6. https://doi.org/10.1016/j.jval.2024.10.3190.

Fowler NH, Dickinson M, Dreyling M, Martinez-Lopez J, Kolstad A, Butler J, et al. Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial. Nat Med. 2022;28:325–32. https://doi.org/10.1038/s41591-021-01622-0.

Google Scholar 

Hirayama AV, Gauthier J, Hay KA, Voutsinas JM, Wu Q, Pender BS, et al. High rate of durable complete remission in follicular lymphoma after CD19 CAR-T cell immunotherapy. Blood. 2019;134:636–40. https://doi.org/10.1182/blood.2019000905.

Google Scholar 

Schuster SJ, Svoboda J, Chong EA, Nasta SD, Mato AR, Anak Ö, et al. Chimeric antigen receptor T cells in refractory B-cell lymphomas. N Engl J Med. 2017;377:2545–54. https://doi.org/10.1056/NEJMoa1708566.

Google Scholar 

Chong EA, Ruella M, Schuster SJ, Lymphoma Program Investigators at the University of Pennsylvania. Five-year outcomes for refractory B-cell lymphomas with CAR T-cell therapy. N Engl J Med. 2021;384:673–4. https://doi.org/10.1056/NEJMc2030164.

Google Scholar 

Fried S, Shkury E, Itzhaki O, Sdayoor I, Yerushalmi R, Shem-Tov N, et al. A. Point-of-care anti-CD19 chimeric antigen receptor T-cell therapy for relapsed/refractory follicular lymphoma. Leuk Lymphoma. 2023;64:1956–63. https://doi.org/10.1080/10428194.2023.2246611.

Google Scholar 

Bannerji R, Arnason JE, Advani RH, Brown JR, Allan JN, Ansell SM, et al. Odronextamab, a human CD20×CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial. Lancet Haematol. 2022;9:e327–39. https://doi.org/10.1016/S2352-3026(22)00072-2.

Google Scholar 

Budde LE, Sehn LH, Matasar M, Schuster SJ, Assouline S, Giri P, et al. Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study. Lancet Oncol. 2022;23:1055–65. https://doi.org/10.1016/S1470-2045(22)00335-7.

Google Scholar 

Goto H, Kumode T, Mishima Y, Kataoka K, Ogawa Y, Kanemura N, et al. Efficacy and safety of mosunetuzumab monotherapy for Japanese patients with relapsed/refractory follicular lymphoma: FLMOON-1. Int J Clin Oncol. 2025;30:389–96. https://doi.org/10.1007/s10147-024-02662-5.

Google Scholar 

Schubert ML, Schmitt M, Wang L, Ramos CA, Jordan K, Müller-Tidow C, et al. Side-effect management of chimeric antigen receptor (CAR) T-cell therapy. Ann Oncol. 2021;32:34–48. https://doi.org/10.1016/j.annonc.2020.10.478.

Google Scholar 

Gazeau N, Liang EC, Wu QV, Voutsinas JM, Barba P, Iacoboni G, et al. Anakinra for refractory cytokine release syndrome or immune effector cell-associated neurotoxicity syndrome after chimeric antigen receptor T cell therapy. Transplant Cell Ther. 2023;29:430–7. https://doi.org/10.1016/j.jtct.2023.04.001.

Google Scholar 

Oluwole OO, Bouabdallah K, Muñoz J, De Guibert S, Vose JM, Bartlett NL, et al. Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B-cell lymphoma. Br J Haematol. 2021;194:690–700. https://doi.org/10.1111/bjh.17527.

Google Scholar 

van Besien HJ, Easwar N, Demetres M, Pasciolla M, Shore T, Leonard JP, et al. Comparative infection risk in CAR T vs bispecific antibodies in B cell lymphoma: a systematic review and meta-analysis. Blood Adv. 2025. https://doi.org/10.1182/bloodadvances.2025016291.

Mohan M, Szabo A, Cheruvalath H, Clennon A, Bhatlapenumarthi V, Patwari A, et al. Effect of Intravenous Immunoglobulin (IVIG) Supplementation on infection-free survival in recipients of BCMA-directed bispecific antibody therapy for multiple myeloma. Blood Cancer J. 2025;15:74. https://doi.org/10.1038/s41408-025-01282-0.

Google Scholar 

Kim J, Cho J, Lee MH, Yoon SE, Kim WS, Kim SJ. CAR T cells vs bispecific antibody as third- or later-line large B-cell lymphoma therapy: a meta-analysis. Blood. 2024;144:629–38. https://doi.org/10.1182/blood.2023023419.

Google Scholar 

Morschhauser F, Tilly H, Chaidos A, McKay P, Phillips T, Assouline S, et al. Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial. Lancet Oncol. 2020;21:1433–42. https://doi.org/10.1016/S1470-2045(20)30441-1.

Google Scholar 

Zinzani PL, Mayer J, Flowers CR, Bijou F, De Oliveira AC, Song Y, et al. ROSEWOOD: a Phase II randomized study of zanubrutinib plus obinutuzumab versus obinutuzumab monotherapy in patients with relapsed or refractory follicular lymphoma. J Clin Oncol. 2023;41:5107–17. https://doi.org/10.1200/JCO.23.00775.

Google Scholar 

Tsang M, Durani U, Day JR, Larson MC, Holets M, Yost KJ, et al. Understanding the patient perspective on treatment preferences for follicular lymphoma. Blood. 2024;144:7598.

Thomas C, Marsh K, Trapali M, Krucien N, Worth G, Cockrum P, et al. Preferences of patients and physicians in the United States for relapsed/refractory follicular lymphoma treatments. Cancer Med. 2024;13:e70177. https://doi.org/10.1002/cam4.70177.

Google Scholar 

Gaballa S, Xue M, Totev TI, Meng Y, Challagulla S, Chen Z, et al. Patient medication preferences in follicular lymphoma (FL) in the United States (USA): a discrete-choice experiment (DCE). Blood. 2024;144:3655.

Jacobson CA, Chavez JC, Sehgal AR, William BM, Munoz J, Salles G, et al. Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial. Lancet Oncol. 2022;23:91–103. https://doi.org/10.1016/S1470-2045(21)00591-X.

Google Scholar 

Ying Z, Zou D, Yang H, Wu J, Guo Y, Li W, et al. Preliminary efficacy and safety of Relmacabtagene autoleucel (Carteyva) in adults with relapsed/refractory follicular lymphoma in China: a Phase I/II clinical trial. Am J Hematol. 2022;97:E436–8. https://doi.org/10.1002/ajh.26711.

Google Scholar